StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Addex Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was CHF 29.97K, down 92.6% from the year before. The highest annual figure on record is CHF 6.04M in fiscal 2018.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 29.97K-92.6%
FY2024Dec 31, 2024CHF 404.10K-74.9%
FY2023Dec 31, 2023CHF 1.61M+13.4%
FY2022Dec 31, 2022CHF 1.42M-51.2%
FY2021Dec 31, 2021CHF 2.92M-19.3%
FY2020Dec 31, 2020CHF 3.61M+30.8%
FY2019Dec 31, 2019CHF 2.76M-54.3%
FY2018Dec 31, 2018CHF 6.04M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2024Jun 30, 2024CHF 115.28K–
Q2 FY2023Jun 30, 2023CHF 630.88K–
Q2 FY2022Jun 30, 2022CHF 183.35K–
Q2 FY2021Jun 30, 2021CHF 992.60K–

More Addex Therapeutics figures

See a number that looks wrong?